Craig-Hallum has initiated coverage on Certara Inc (CERT) with a Buy rating, marking the firm's first assessment of the company. This action, taken on September 28, 2025, comes as Certara continues to expand its role in the health care industry, where it provides software and technology-enabled services for drug developers.
Headquartered in Radnor, Pennsylvania, Certara employs 1,487 full-time workers and went public on December 11, 2020. The company leverages biosimulation software and technology to enhance drug discovery and development, serving approximately 2,400 clients, including biopharmaceutical firms and regulatory agencies across 70 countries.
Currently, Certara's shares are trading at $8.25, with a market capitalization of $1.3 billion. The company's price-to-earnings ratio stands at 117.58, and it reported an earnings per share (EPS) of $0.07 for the trailing twelve months. Looking ahead, Certara's upcoming earnings reports are scheduled for May 4, 2026, with an EPS estimate of $0.14 and revenue expectations of $113.3 million.
Analyst ratings and price targets are based on research and financial models, providing insights into potential investment merit. However, these assessments are subject to change as new information emerges. Investors are encouraged to consider various factors, including company fundamentals and market dynamics, when making decisions.
As of November 1, 2025, the analyst consensus for Certara stands at 3 Strong Buy, 8 Buy, and 7 Hold ratings, reflecting a generally favorable outlook among analysts.